Skip to main
BMEA
BMEA logo

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 29%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. exhibits a strong potential for growth due to the promising clinical results of its lead drug candidate, icovamenib, which demonstrates enhanced efficacy when combined with GLP-1-based therapies, leading to significant reductions in HbA1c levels and improved glycemic control. Additionally, the drug's ability to heighten the expression of GLP-1 receptors in human islets may allow for reduced dosing requirements and improved tolerability, addressing a critical need within the therapeutic landscape for diabetes and obesity management. Furthermore, the company's innovative approach using the FUSION System discovery platform positions it well for the development of advanced oral covalent small-molecule drugs, potentially solidifying its footprint in the growing market for diabetes and obesity treatments.

Bears say

Biomea Fusion Inc is facing significant challenges that contribute to a negative outlook on its stock, primarily related to the uncertainties surrounding its clinical trials, particularly for its lead drug candidate, icovamenib. The company's valuation has been lowered to $16, reflecting concerns about potential market limitations for type 1 diabetes patients and the possibility of failed or inconclusive trial results. Additionally, the risk of inadequate funding to advance its drug development or the need for dilutive capital raises further exacerbates financial uncertainties, necessitating a cautious stance on the stock.

BMEA has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 29% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 14 analysts, BMEA has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.